Cover Image

Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study

Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost n...

Full description

Saved in:
Bibliographic Details
Main Authors: Frankenstein, Lutz (Author) , Katus, Hugo (Author) , Grundtvig, M. (Author) , Hole, T. (Author) , de Blois, J. (Author) , Schellberg, Dieter (Author) , Atar, D. (Author) , Zugck, Christian (Author) , Agewall, S. (Author)
Format: Article (Journal)
Language:English
Published: 07 June 2013
In: European journal of clinical pharmacology
Year: 2013, Volume: 69, Issue: 10, Pages: 1747-1755
ISSN:1432-1041
DOI:10.1007/s00228-013-1512-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00228-013-1512-x
Get full text
Author Notes:L. Frankenstein, H.A. Katus, M. Grundtvig, T. Hole, J. de Blois, D. Schellberg, D. Atar, C. Zugck, S. Agewall, on behalf of the Norwegian Heart Failure Registry steering committee

MARC

LEADER 00000caa a2200000 c 4500
001 1756677018
003 DE-627
005 20230426092553.0
007 cr uuu---uuuuu
008 210430s2013 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00228-013-1512-x  |2 doi 
035 |a (DE-627)1756677018 
035 |a (DE-599)KXP1756677018 
035 |a (OCoLC)1341407461 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Frankenstein, Lutz  |d 1973-  |e VerfasserIn  |0 (DE-588)124198937  |0 (DE-627)63440766X  |0 (DE-576)328373281  |4 aut 
245 1 0 |a Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction  |b a propensity score-matched cohort study  |c L. Frankenstein, H.A. Katus, M. Grundtvig, T. Hole, J. de Blois, D. Schellberg, D. Atar, C. Zugck, S. Agewall, on behalf of the Norwegian Heart Failure Registry steering committee 
264 1 |c 07 June 2013 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.04.2021 
520 |a Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost no beta-blockers. Since pharmacological properties differ between eplerenone and spironolactone, the prognostic benefit of spironolactone added to this baseline combination therapy needs clarification. 
700 1 |a Katus, Hugo  |d 1951-  |e VerfasserIn  |0 (DE-588)108916618  |0 (DE-627)577155040  |0 (DE-576)289625076  |4 aut 
700 1 |a Grundtvig, M.  |e VerfasserIn  |4 aut 
700 1 |a Hole, T.  |e VerfasserIn  |4 aut 
700 1 |a de Blois, J.  |e VerfasserIn  |4 aut 
700 1 |a Schellberg, Dieter  |e VerfasserIn  |0 (DE-588)1028373023  |0 (DE-627)730619974  |0 (DE-576)375906010  |4 aut 
700 1 |a Atar, D.  |e VerfasserIn  |4 aut 
700 1 |a Zugck, Christian  |e VerfasserIn  |0 (DE-588)1028371993  |0 (DE-627)730617548  |0 (DE-576)176412999  |4 aut 
700 1 |a Agewall, S.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t European journal of clinical pharmacology  |d Berlin : Springer, 1968  |g 69(2013), 10, Seite 1747-1755  |h Online-Ressource  |w (DE-627)253722829  |w (DE-600)1459058-X  |w (DE-576)072372613  |x 1432-1041  |7 nnas  |a Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction a propensity score-matched cohort study 
773 1 8 |g volume:69  |g year:2013  |g number:10  |g pages:1747-1755  |g extent:9  |a Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction a propensity score-matched cohort study 
856 4 0 |u https://doi.org/10.1007/s00228-013-1512-x  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210430 
993 |a Article 
994 |a 2013 
998 |g 1028371993  |a Zugck, Christian  |m 1028371993:Zugck, Christian  |d 910000  |d 910100  |e 910000PZ1028371993  |e 910100PZ1028371993  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 1028373023  |a Schellberg, Dieter  |m 1028373023:Schellberg, Dieter  |d 910000  |d 910100  |e 910000PS1028373023  |e 910100PS1028373023  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 108916618  |a Katus, Hugo  |m 108916618:Katus, Hugo  |d 910000  |d 910100  |e 910000PK108916618  |e 910100PK108916618  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 124198937  |a Frankenstein, Lutz  |m 124198937:Frankenstein, Lutz  |d 910000  |d 910600  |e 910000PF124198937  |e 910600PF124198937  |k 0/910000/  |k 1/910000/910600/  |p 1  |x j 
999 |a KXP-PPN1756677018  |e 3920377141 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"07 June 2013"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["organ of European Association for Clinical Pharmacology and Therapeutics (EACPT)"]},"part":{"year":"2013","extent":"9","pages":"1747-1755","text":"69(2013), 10, Seite 1747-1755","issue":"10","volume":"69"},"origin":[{"dateIssuedKey":"1968","publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedDisp":"1968-","publisher":"Springer"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"id":{"zdb":["1459058-X"],"eki":["253722829"],"issn":["1432-1041"]},"title":[{"title_sort":"European journal of clinical pharmacology","title":"European journal of clinical pharmacology"}],"disp":"Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction a propensity score-matched cohort studyEuropean journal of clinical pharmacology","note":["Gesehen am 11.10.05"],"titleAlt":[{"title":"Clinical pharmacology"},{"title":"EJCP"},{"title":"Pharmacologia clinica"}],"pubHistory":["1.1968/69 -"],"recId":"253722829"}],"name":{"displayForm":["L. Frankenstein, H.A. Katus, M. Grundtvig, T. Hole, J. de Blois, D. Schellberg, D. Atar, C. Zugck, S. Agewall, on behalf of the Norwegian Heart Failure Registry steering committee"]},"person":[{"family":"Frankenstein","roleDisplay":"VerfasserIn","given":"Lutz","role":"aut","display":"Frankenstein, Lutz"},{"given":"Hugo","display":"Katus, Hugo","role":"aut","roleDisplay":"VerfasserIn","family":"Katus"},{"display":"Grundtvig, M.","role":"aut","given":"M.","roleDisplay":"VerfasserIn","family":"Grundtvig"},{"family":"Hole","roleDisplay":"VerfasserIn","given":"T.","display":"Hole, T.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"de Blois","given":"J.","display":"de Blois, J.","role":"aut"},{"display":"Schellberg, Dieter","role":"aut","given":"Dieter","family":"Schellberg","roleDisplay":"VerfasserIn"},{"family":"Atar","roleDisplay":"VerfasserIn","given":"D.","role":"aut","display":"Atar, D."},{"display":"Zugck, Christian","role":"aut","given":"Christian","roleDisplay":"VerfasserIn","family":"Zugck"},{"display":"Agewall, S.","role":"aut","given":"S.","roleDisplay":"VerfasserIn","family":"Agewall"}],"physDesc":[{"extent":"9 S."}],"note":["Gesehen am 30.04.2021"],"title":[{"title":"Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction","title_sort":"Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction","subtitle":"a propensity score-matched cohort study"}],"id":{"doi":["10.1007/s00228-013-1512-x"],"eki":["1756677018"]},"recId":"1756677018"} 
SRT |a FRANKENSTEASSOCIATIO0720 

Similar Items